共 50 条
- [21] Letrozole is cost-effective versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: BIG-1-98EJC SUPPLEMENTS, 2005, 3 (02): : 96 - 96Karnon, J.Johnston, S. R. D.Delea, T.Barghout, V.Thomas, S.Papo, N. L.
- [22] ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerBREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) : 543 - 555Leyland-Jones, BrianGray, Kathryn P.Abramovitz, MarkBouzyk, MarkYoung, BrandonLong, BradleyKammler, RoswithaDell'Orto, PatriziaBiasi, Maria OliviaThuerlimann, BeatHarvey, VernonNeven, PatrickArnould, LaurentMaibach, RudolfPrice, Karen N.Coates, Alan S.Goldhirsch, AronGelber, Richard D.Pagani, OliviaViale, GiuseppeRae, James M.Regan, Meredith M.
- [23] ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancerBreast Cancer Research and Treatment, 2015, 154 : 543 - 555Brian Leyland-JonesKathryn P. GrayMark AbramovitzMark BouzykBrandon YoungBradley LongRoswitha KammlerPatrizia Dell’OrtoMaria Olivia BiasiBeat ThürlimannVernon HarveyPatrick NevenLaurent ArnouldRudolf MaibachKaren N. PriceAlan S. CoatesAron GoldhirschRichard D. GelberOlivia PaganiGiuseppe VialeJames M. RaeMeredith M. Regan
- [24] Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1-98JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Coates, A. S.Mouridsen, H.Sun, Z.Rabaglio, M.Castiglione-Gertsch, M.Thurlimann, B.Mauriac, L.Price, N.Colleoni, M.Smith, I.
- [25] Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancerBREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 339 - 339Viale, G.Regan, M.Dell'Orto, P.Curto, Del B.Braye, S.Orosz, Z.Brown, R.Olszewski, W. P.Knox, F.Oehlschlegel, C.Thurlimann, B.
- [26] Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Ribi, K.Aldridge, J.Phillips, K.Sun, Z.Thompson, A. M.Harvey, V. J.Thuerlimann, B.Cardoso, F.Coates, A. S.Bernhard, J.
- [27] Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancerBREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S13 - S14Viale, GRegan, MDell'Orto, PDel Curto, BBraye, SOrosz, ZBrown, ROlszewski, WPKnox, FOehlschlegel, CThürlimann, B
- [28] Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancerBREAST CANCER RESEARCH, 2011, 13 (03)Regan, Meredith M.Price, Karen N.Giobbie-Hurder, AnitaThuerlimann, BeatGelber, Richard D.
- [29] Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancerBreast Cancer Research, 13Meredith M ReganKaren N PriceAnita Giobbie-HurderBeat ThürlimannRichard D Gelber
- [30] Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)ANNALS OF ONCOLOGY, 2012, 23 (06) : 1474 - +Zaman, K.Thuerlimann, B.Huober, J.Schoenenberger, A.Pagani, O.Luethi, J.Simcock, M.Giobbie-Hurder, A.Berthod, G.Genton, C.Brauchli, P.Aebi, S.